Connect with us

Health

Oxford Launches World’s First Human Trial of Vaccine Against Bundibugyo Ebola

Published

on

Scientists at the University of Oxford have launched the world’s first human clinical trial of a vaccine targeting the Bundibugyo strain of Ebola as health authorities work to contain a growing outbreak in the Democratic Republic of the Congo and Uganda.

The Phase I trial will evaluate the vaccine’s safety and its ability to trigger an immune response in 50 healthy adult volunteers aged between 18 and 55. Researchers have begun recruiting participants, with vaccinations expected to start in the coming weeks after regulatory approval for the study.

The trial comes as the Bundibugyo Ebola outbreak continues to expand across Central Africa. According to the Democratic Republic of the Congo’s Ministry of Health, 1,926 confirmed cases and 702 deaths had been recorded across five provinces as of July 11. Uganda reported 20 confirmed infections, including two deaths, on July 12. Health officials have identified 10 provinces in Congo, including the capital Kinshasa, as high-risk areas.

The University of Oxford’s Vaccine Group said the study represents the first effort to test a vaccine specifically designed to protect against the Bundibugyo strain in humans. While vaccines exist for other Ebola virus species, no approved vaccine currently targets Bundibugyo Ebolavirus.

Nicole Lurie, Executive Director of Preparedness and Response at the Coalition for Epidemic Preparedness Innovations (CEPI), described the trial as an important step in the international response to the outbreak.

“Every step that brings a safe and effective vaccine closer helps strengthen our ability to protect vulnerable communities, save lives and bring this outbreak under control,” Lurie said, adding that Oxford’s work marks a significant milestone in efforts to combat the disease.

See also  Belgium's Food Agency Issues Warning After Ghent Suggests Eating Christmas Trees

Researchers are also preparing additional clinical studies in Uganda, subject to approval from local regulators. Those trials are expected to be carried out through a partnership involving the Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene and Tropical Medicine’s Uganda Research Unit.

Jean Kaseya, Director General of the Africa Centres for Disease Control and Prevention, welcomed the progress while stressing the importance of maintaining rigorous scientific and regulatory standards.

He said that although early-stage clinical trials will not provide an immediate solution for communities currently affected by the outbreak, they remain essential for developing medical tools capable of responding to both the current emergency and future Ebola outbreaks.

The Bundibugyo strain is one of several Ebola virus species known to infect humans and has caused multiple outbreaks in Africa over the past two decades. Public health officials continue to focus on surveillance, patient care, contact tracing and infection control measures while researchers work to develop vaccines and treatments that can help reduce the impact of the disease.

The Oxford trial is expected to provide initial data on the vaccine’s safety and immune response, laying the foundation for larger studies if the early results prove successful.

Health

European Authorities Dismantle International Tobacco Smuggling Networks, Seize Millions of Illegal Cigarettes

Published

on

European law enforcement agencies have dismantled two international criminal networks involved in the production and distribution of counterfeit tobacco products, seizing 20 million illegal cigarettes and 38.4 tonnes of tobacco during a coordinated operation centered in Spain.

The operation, announced by the European Union’s Anti-Fraud Office (OLAF), targeted an illicit supply chain believed to be worth around €10 million. Investigators say the groups were involved in manufacturing, transporting and distributing counterfeit cigarettes across several European countries.

The crackdown was carried out through close cooperation between law enforcement agencies from Spain, Poland, Portugal and Lithuania, with support from OLAF and Europol.

During the operation last month, officers conducted 23 coordinated searches at residential properties, commercial buildings and industrial warehouses across the Spanish provinces of Alicante, Cuenca, Huelva, Murcia, Sevilla and Toledo.

Authorities recovered 20 million counterfeit cigarettes along with 38.4 tonnes of tobacco leaf and processed tobacco intended for illegal cigarette production. Investigators also seized tobacco manufacturing machinery, 18 vehicles, encrypted electronic devices, €170,000 in cash and several firearms believed to be connected to the criminal organizations.

A total of 50 suspects were arrested during the raids. Two of those arrested have since been transferred to Polish authorities as part of the cross-border investigation.

Officials believe the dismantled networks played a major role in supplying counterfeit tobacco products to illegal markets across Europe, depriving governments of tax revenue while strengthening organized crime groups involved in illicit trade.

OLAF Director-General Petr Klement said counterfeit tobacco products present both financial and public health risks.

“Smoking is dangerous,” Klement said. “Smoking counterfeit cigarettes is even worse.”

See also  Eli Lilly’s Oral Pill Shows Strong Weight Loss Results in Clinical Trials

He added that the illegal trade not only exposes consumers to unregulated products but also diverts significant tax revenues away from public services while providing income for organized criminal networks.

The investigation reflects growing cooperation among European authorities to combat cross-border financial crime and illicit manufacturing. Counterfeit tobacco remains one of the most profitable illegal markets in Europe because of high consumer demand and substantial differences in tobacco taxation between countries.

Europol and participating agencies have increased intelligence sharing and joint operations in recent years to identify production facilities, disrupt supply routes and prosecute those responsible for illegal tobacco trafficking.

Officials said the investigation remains active and further arrests or seizures have not been ruled out as investigators continue examining evidence collected during the searches.

Authorities have urged the public to remain cautious when purchasing tobacco products from unofficial sources, warning that counterfeit cigarettes may contain harmful substances that do not meet safety standards and often finance wider criminal activities, including money laundering, illegal arms trafficking and other forms of organized crime.

The latest operation is being viewed as one of the largest coordinated actions against counterfeit tobacco networks in Europe this year, highlighting the scale of the illicit trade and the continued efforts by international authorities to dismantle criminal organizations operating across national borders.

Continue Reading

Health

New Blood Test Shows Promise for Earlier Endometriosis Diagnosis

Published

on

A new blood test that identifies a unique hormone pattern linked to endometriosis could transform the diagnosis of the condition, with researchers reporting an accuracy rate of more than 95 percent in detecting the disease.

The findings offer hope for millions of women worldwide who often face years of uncertainty before receiving a diagnosis. Endometriosis affects an estimated 190 million people globally and is commonly diagnosed only after extensive medical examinations or surgery.

The condition occurs when tissue similar to the lining of the uterus grows outside the uterus, causing chronic pain, heavy menstrual bleeding, fertility problems and other complications. Current diagnostic methods typically include pelvic examinations, ultrasound scans, magnetic resonance imaging (MRI) or laparoscopy, a minimally invasive surgical procedure used to examine the pelvic organs.

According to the World Health Organization, diagnosing endometriosis can take up to 12 years in some cases, particularly in low- and middle-income countries where access to specialist care remains limited. In the United Kingdom, patients wait an average of more than nine years before receiving a confirmed diagnosis.

Researchers believe the newly developed blood test could significantly shorten that timeline by identifying a distinctive hormonal signature found only in women with the condition.

The study, conducted by scientists at the University of Edinburgh, examined blood samples from 159 women with confirmed endometriosis and 57 women without the disease. Instead of focusing solely on estrogen, which has long been associated with endometriosis, the researchers investigated the role of androgens, a group of hormones that includes testosterone and plays an important role in reproductive health, muscle development and bone strength.

See also  Processed Red Meat Consumption Linked to Increased Dementia Risk, Study Finds

Particular attention was given to 11-oxygenated androgens, hormones produced by the adrenal glands located above the kidneys.

The research revealed that women with endometriosis consistently displayed a distinct hormonal fingerprint, including elevated levels of 11-ketotestosterone, an androgen involved in muscle development and reproductive organ growth.

Using this hormone profile, researchers were able to distinguish women with endometriosis from those without the condition with an accuracy exceeding 95 percent.

Douglas Gibson, co-author of the study from the University of Edinburgh, described the findings as a significant advance in understanding the disease. He said the discovery could pave the way for earlier diagnosis as well as the development of new treatment options for patients.

Emma Cox, chief executive of Endometriosis UK, welcomed the research, saying women have faced unacceptably long waits for diagnosis for many years. She noted that delays often postpone treatment and allow the disease to progress, making symptoms more difficult to manage.

Although additional research and larger clinical trials will be needed before the blood test becomes part of routine medical care, experts believe the findings represent an important step toward faster, less invasive diagnosis. If validated in future studies, the test could reduce the need for surgical procedures and help patients begin treatment much earlier in the course of the disease.

Continue Reading

Health

Study Finds Men Far More Likely Than Women to ‘Hit the Wall’ in Marathons

Published

on

Men are significantly more likely than women to experience the dreaded marathon phenomenon known as “hitting the wall,” according to a large international study that analysed the performances of more than 870,000 runners over a 26-year period.

The research, published in the journal Scientific Reports, examined the results of 873,334 finishers in the Berlin Marathon between 1999 and 2025. Researchers found that although men generally complete marathons faster than women, they are much more likely to suffer a dramatic slowdown during the later stages of the race because of less consistent pacing.

According to the study, men are almost twice as likely overall to experience a sudden decline in speed during a marathon. In some performance categories, they were found to be up to six times more likely than women to “hit the wall,” a term commonly used to describe severe physical exhaustion caused by depleted energy stores.

Researchers said the findings point to differences in race strategy rather than physical ability alone. Men were more likely to begin races at an aggressive pace, increasing the risk of fatigue before reaching the finish line.

The study concluded that “men, regardless of performance level, are more prone to aggressive pacing and catastrophic deceleration.” The authors suggested that greater willingness to take risks and higher levels of confidence may encourage many male runners to start faster than they can realistically sustain over the full 42.195-kilometre distance.

Women, on the other hand, displayed more controlled pacing throughout the race. Researchers found they were better at regulating their effort from start to finish, reducing the likelihood of a significant loss of speed during the closing kilometres.

See also  White House Rejects Report It Blocked Return of Ebola-Infected US Doctor

The report described women as showing “superior self-pacing abilities and greater resistance to decision-making fatigue,” characteristics that can be particularly valuable during endurance events.

Maintaining a steady pace is widely regarded as one of the most important factors in marathon performance. Running too quickly during the opening stages can rapidly consume the body’s glycogen reserves, leaving athletes without enough energy to sustain their speed in the final part of the race.

The researchers noted that pacing is “the most critical tactical determinant of performance” in marathon running, making strategic decision-making just as important as physical fitness.

The findings could influence how coaches and runners prepare for long-distance races. Rather than focusing solely on speed, the study suggests that adopting a realistic race plan and maintaining a consistent pace throughout the event may improve overall performance and reduce the chances of a late-race collapse.

With marathon participation continuing to grow worldwide, the researchers believe a better understanding of pacing strategies could help runners of all abilities achieve stronger and more consistent results.

Continue Reading

Trending